HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells (Q42945834)

11 November 2017

title

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells (English)

1 reference

11 November 2017

0 references

1 reference

Y. Furukawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

R. Shimizu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

J. Kikuchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

T. Wada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

K. Ozawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

Y. Kano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686505

17 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20686505

17 June 2024

publication date

5 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

1 reference

11 November 2017

1 reference

11 November 2017

page(s)

1760-1768

1 reference

B lymphocytes: how they develop and function.

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Rituximab therapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

The role of histone deacetylases (HDACs) in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

A review of valproate in psychiatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.157

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.157

1 reference

Dimensions Publication ID

11 November 2017

1017826637

0 references

1 reference